Matrixyl Peptide: The Complete Guide to Original, 3000 and Synthe'6

Matrixyl is the trade name for a family of anti-aging peptide ingredients developed by the French cosmetic-ingredient company Sederma (a Croda business). At its core, Matrixyl refers to palmitoyl pentapeptide-4, a short chain of five amino acids—lysine, threonine, threonine, lysine, serine (the KTTKS sequence)—attached to a palmitic acid (palmitoyl) tail. The peptide portion is derived from a fragment of type I procollagen, the most abundant structural protein in human skin.

The KTTKS sequence alone is water-soluble but penetrates skin poorly. By adding a 16-carbon palmitoyl lipid, chemists created a molecule (Pal-KTTKS) that is amphiphilic—part water-loving, part fat-loving—so it can cross the lipid-rich stratum corneum and reach the living epidermis and dermis where fibroblasts reside. This lipidation is the single most important design choice behind Matrixyl's activity as a topical ingredient.

It is important to understand what Matrixyl is not. It is not an injectable research peptide, not a hormone, and not a drug. It is a cosmetic ingredient used in leave-on serums and creams. Its purpose is to send a biological "repair" signal to skin cells, a mechanism that places it in the broader category of signal peptides or matrikines. To understand where it fits, it helps to review how cosmetic peptides are classified.

Since the original launch in the early 2000s, Sederma has released successive generations—Matrixyl 3000 and Matrixyl Synthe'6—each combining different peptides to broaden the range of skin-matrix components they stimulate. When a product simply says "Matrixyl," it may refer to any of these, which is why reading the full ingredient (INCI) list matters. We break down each version in detail below.

This article is for educational purposes only and is not medical advice. Consult a qualified healthcare or dermatology professional before starting any new skincare regimen.

Matrixyl belongs to a class of molecules called matrikines—peptide fragments that are released when the skin's extracellular matrix (ECM) is broken down. In healthy young skin, collagen and elastin are constantly remodeled. When collagen is degraded by enzymes, small peptide fragments such as KTTKS are liberated. Fibroblasts interpret these fragments as a message that says, in effect, "structural protein has been lost—rebuild it."

The pentapeptide KTTKS is a subfragment of the C-terminal propeptide of type I procollagen. In cell-culture work, this fragment has been shown to upregulate the production of type I and type III collagen, fibronectin, and glycosaminoglycans. In other words, Matrixyl doesn't passively fill wrinkles or coat the skin; it acts upstream as a signaling molecule that nudges the skin's own machinery to synthesize fresh matrix proteins. This is a fundamentally different mechanism from occlusive moisturizers or exfoliating acids.

Because it works by signaling rather than by paralyzing muscle or delivering an antioxidant, Matrixyl is often described as a collagen-boosting signal peptide. This distinguishes it from neuromodulating peptides like Argireline, which target the machinery of muscle contraction to soften expression lines, and from copper-carrier peptides like GHK-Cu, which combine tissue-remodeling signals with copper delivery. Matrixyl's lane is matrix stimulation.

The successive Matrixyl generations expand this signaling. Matrixyl 3000 pairs two peptides—Pal-GHK (palmitoyl tripeptide-1) and Pal-GQPR (palmitoyl tetrapeptide-7)—that together aim to both stimulate matrix production and modulate the inflammatory signaling (such as interleukin-6) associated with aging. Matrixyl Synthe'6 uses palmitoyl tripeptide-38 to influence six distinct constituents of the dermal-epidermal junction and matrix: collagen I, collagen III, collagen IV, fibronectin, hyaluronic acid, and laminin 5.

A realistic view of the mechanism matters. Topical peptides face a genuine bioavailability challenge: the skin barrier is designed to keep large, charged molecules out. Palmitoylation improves penetration, but the amount of intact peptide reaching the dermis is modest. This is why Matrixyl's effects are cumulative and subtle rather than immediate—a point we return to when discussing timelines. For a foundational overview, see our explainer on peptides in cosmetics.

Three main generations of Matrixyl exist, and they are chemically distinct. Confusing them is the most common mistake shoppers make, so it is worth understanding each on its own terms.

Matrixyl (original) is a single peptide: palmitoyl pentapeptide-4, or Pal-KTTKS. (Older literature calls it palmitoyl pentapeptide-3; the name changed with an INCI revision, but the molecule is the same.) It targets primarily type I and III collagen and fibronectin. It has the longest track record and the most independent supporting literature of the three.

Matrixyl 3000 is a blend of two peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is synergy—one peptide drives matrix synthesis while the other helps regulate the low-grade inflammation and glycation-related damage of aged skin. Sederma's internal data report that Matrixyl 3000 increases collagen synthesis by up to 117%. It has become the most widely used version in mass-market serums. Our dedicated Matrixyl 3000 monograph covers it in depth.

Matrixyl Synthe'6 is built around palmitoyl tripeptide-38 and is marketed as a "six-in-one" matrix stimulator, influencing collagen I, III, and IV, fibronectin, hyaluronic acid, and laminin 5. Because it also acts on components of the dermal-epidermal junction (laminin 5, collagen IV), Sederma positions it especially for smoothing established, deeper wrinkles such as forehead and crow's-feet lines.

The table below summarizes the differences:

Practically, none is universally "best." Matrixyl 3000 is the sensible default for broad anti-aging; original Matrixyl is a well-studied choice for fine lines; Synthe'6 targets more entrenched wrinkles. Many formulas now combine two of them, which is chemically compatible.

Matrixyl has more supporting data than most cosmetic peptides, but the evidence base should be read with a critical eye. A large share of the strongest efficacy figures come from the manufacturer, Sederma, rather than from independent, placebo-controlled trials, and cosmetic studies are generally smaller and shorter than pharmaceutical trials.

The foundational mechanistic work predates the branding: Katayama and colleagues showed in the early 1990s that the KTTKS pentapeptide stimulates extracellular-matrix production—collagen and fibronectin—in fibroblast culture, establishing the biological rationale that Sederma later commercialized. This is the scientific bedrock of the ingredient.

On the manufacturer side, Sederma reports that a 3% Matrixyl solution produced up to a 37% reduction in wrinkle volume and reductions in wrinkle depth and density over roughly two months, and that Matrixyl 3000 increased collagen synthesis by up to 117% in their models. These numbers are widely cited but originate from company testing, so they should be treated as promising rather than definitive.

Independent human data exist and are more measured. A frequently cited split-face, double-blind study by Robinson and colleagues found that topical Pal-KTTKS improved the appearance of photoaged facial skin—reducing wrinkles and fine lines relative to vehicle—over 12 weeks, with good tolerability. Broader reviews of topical peptides, such as those by Gorouhi and Maibach and by Lintner, place Matrixyl among the better-supported cosmetic peptides while noting that effect sizes are modest and penetration remains a limiting factor.

The honest summary: Matrixyl reliably stimulates matrix proteins in vitro, is well tolerated, and shows measurable but moderate wrinkle improvement in human use. It is not a substitute for prescription retinoids or clinical procedures, and headline percentages should be understood as best-case manufacturer figures. For a like-for-like comparison against a gold-standard active, see our article on peptides versus retinol.

Matrixyl is frequently compared with two other popular cosmetic peptides—Argireline and GHK-Cu—but the three occupy different mechanistic lanes and are complementary rather than interchangeable.

Argireline (acetyl hexapeptide-3/8) is a neuromodulating peptide. It works by interfering with the SNARE protein complex involved in neurotransmitter release, subtly reducing the muscle contractions that create dynamic expression lines. Clinical reports describe reductions in wrinkle depth of up to about 30% over 30 days. Its strength is dynamic lines—forehead and around the eyes—not collagen loss. Matrixyl, by contrast, does nothing to muscle; it targets the structural matrix. This is exactly why the two are often layered together, and why we cover the head-to-head in Matrixyl vs Argireline.

GHK-Cu (copper tripeptide-1) is a copper-carrying signal peptide discovered by Loren Pickart in 1973. It combines matrix-remodeling signals with the delivery of copper, a cofactor for enzymes such as lysyl oxidase involved in collagen and elastin cross-linking. In fibroblast studies it has been reported to stimulate collagen synthesis substantially and to regulate a large number of genes. GHK-Cu overlaps with Matrixyl in the "stimulate repair" goal but adds copper-dependent effects and antioxidant/anti-inflammatory activity. See our GHK-Cu guide for detail.

The table clarifies the distinctions:

Because the mechanisms differ, combining them is a rational strategy rather than redundancy: Matrixyl for structure, Argireline for expression lines, GHK-Cu for repair. One caution—GHK-Cu can be destabilized by strong reducing agents and some direct-acid actives, so formulation order matters when stacking. Our guide to peptide stacking covers compatible combinations.

Matrixyl's real-world performance depends heavily on formulation—concentration, pH, and the accompanying ingredients—because a signal peptide can only work if it survives the product and penetrates the skin.

Concentration. A key source of confusion is that "Matrixyl" as sold to formulators is already a dilute solution (the peptide is a minor fraction of the branded raw material, delivered in a glycerin/water base). When a serum lists "5% Matrixyl 3000," that refers to 5% of the branded solution, not 5% pure peptide. Typical effective use levels of the branded material fall in the 3–8% range; the manufacturer's benchmark efficacy studies were run around 3%. Higher percentages of the branded solution are not necessarily better, and beyond a point offer diminishing returns.

pH. Matrixyl peptides are most stable and best tolerated in a mildly acidic environment, roughly pH 5.0–6.5, which also aligns with the skin's natural acid mantle. Extremes of pH can hydrolyze the peptide bond over time, so well-buffered formulas last longer. This is one reason Matrixyl should generally not be layered directly with very low-pH exfoliating acids in the same step.

Compatible partners. Matrixyl combines well with humectants (hyaluronic acid, glycerin, panthenol), niacinamide, and other signal peptides. It is chemically compatible with most routines. Where care is needed is with direct-acid actives (glycolic, salicylic, high-strength vitamin C at very low pH), which are best used at a different time of day to preserve peptide integrity, and—if you also use GHK-Cu—with strong reducing antioxidants that can disrupt the copper complex.

• Good pairings: hyaluronic acid, niacinamide, panthenol, ceramides, Argireline, Matrixyl Synthe'6 + Matrixyl 3000 together.
• Separate by time of day: low-pH AHAs/BHAs, high-strength L-ascorbic acid, prescription retinoids (for tolerance, not chemistry).
• Handle with care alongside: GHK-Cu plus strong reducing agents.

Packaging. Peptides degrade with prolonged light and air exposure. Opaque, airless pump packaging protects potency far better than open jars. If you want to model concentrations or reconstitution for research contexts, our Peptide Lab calculator can help. Note that these tools are educational and Matrixyl itself is a topical cosmetic, not an injectable.

Matrixyl is a leave-on active, used once or twice daily. Because it is a gentle signal peptide rather than an irritant, it does not require the gradual "ramp-up" that retinoids do and can typically be used morning and evening from the start.

A simple, effective routine is: cleanse, apply any water-based hydrating layer or a Matrixyl serum onto slightly damp skin, wait a minute for absorption, then seal with a moisturizer. In the morning, always finish with a broad-spectrum SPF 30+ sunscreen—collagen support is undermined by ongoing UV damage, and sun protection is the single most impactful anti-aging step. Matrixyl pairs naturally with sunscreen because it has no photosensitizing effect.

Timeline. Manage expectations realistically. Matrixyl works by slowly stimulating new matrix synthesis, and collagen turnover in skin is measured in weeks to months, not days. A reasonable expectation looks like this:

Consistency is decisive. Because the peptide signal must be delivered repeatedly to sustain matrix stimulation, occasional use yields little. If you stop, the stimulus stops and gains gradually fade, as they would with any collagen-supporting active. For product-selection guidance, see our roundup of the best peptide serums.

Finally, Matrixyl is best viewed as one component of a complete regimen—cleanser, antioxidant, moisturizer, sunscreen—rather than a standalone fix. It layers well with retinoids and vitamin C (used at appropriate times) for a multi-pathway approach to photoaging.

Among cosmetic actives, the Matrixyl peptides have a favorable safety and tolerability profile. They are non-irritating for most users, do not cause photosensitivity, and are not associated with the stinging, peeling, or purging that can accompany retinoids and acids. This gentleness is one reason they are recommended for sensitive skin and for people who cannot tolerate stronger actives.

That said, no ingredient is universally free of reactions. As with any leave-on product, a small number of people may experience irritation or contact sensitivity—often to other ingredients in the formula (preservatives, fragrance) rather than to the peptide itself. A patch test on the inner forearm for a few days before facial use is a sensible precaution, particularly for reactive skin.

It is important to frame Matrixyl accurately: it is a topical cosmetic ingredient, not a drug, an injectable, or a treatment for any medical condition. Cosmetic claims are limited to appearance—reducing the look of fine lines and improving firmness and texture—not to altering skin structure in a medical sense. Matrixyl is not FDA- or EMA-approved as a therapeutic because it is not marketed as one; it is regulated as a cosmetic. Products should not claim to "cure" wrinkles or replace medical care.

Some general precautions apply. During pregnancy or breastfeeding, or if you have a diagnosed skin condition, discuss any new active with a healthcare professional first. Regulatory status for cosmetic peptides is broadly permissive across the US and EU, but formulation quality varies widely between brands, and the peptide content of a finished product is rarely disclosed precisely.

This guide is educational and does not constitute medical advice. Individual results vary, and you should consult a qualified dermatologist or healthcare professional about your specific skin. See our medical disclaimer for details.